| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Radiology, College of Medicine, University of Cincinnati, Cincinnati, Ohio
Oak Ridge Associated Universities, Oak Ridge, Tennessee
University of Chicago, Chicago, Illinois A task group of the MIRD Committee, Society of Nuclear Medicine
Correspondence: For reprints contact: David A. Weber, PhD, Chairman, MIRD Committee, Brookhaven National Laboratories, Nuclear Medicine Division, Medical Department, Bldg. 490, Upton, NY 11973.
ABSTRACT
The constant-volume urinary bladder model in the standard MIRD phantom has recognized limitations. Various investigators have developed detailed models incorporating more physiologically realistic features such as expanding bladder contents and residual volume, and variable urinary input rate, initial volume and first void time. We have reviewed these published models and have developed a new model incorporating these factors. The model consists of a spherical source with variable volume to simulate the bladder contents and a wall represented by a spherical shell of constant volume. The wall thickness varies as the source expands or contracts. The model provides for variable urine entry rate (three different hydration states), initial bladder contents volume, residual volume and first void time. The voiding schedule includes an extended nighttime gap during which the urine entry rate is reduced to one-half the daytime rate. Radiation dose estimates have been calculated for the bladder wall surface (including photon and electron components) and at several depths in the wall (electron component) for [18F]FDG, 99mTc-DTPA, 99mTc-HEDP, [99mTc]pertechnetate 99mTc-RBCs, 99mTc-glucoheptonate, 99mTc-MAG3, [123I]/[124I]/[131I]OIH and sodium [131I]iodide(Nal). The initial bladder volume and first void time that provide the lowest radiation dose to the bladder wall are determined separately for each compound to give guidance for establishing dose reduction protocols.
This article has been cited by other articles:
|
|
 |
|
  G. Paganelli, M. Ferrari, L. Ravasi, M. Cremonesi, C. De Cicco, V. Galimberti, G. Sivolapenko, A. Luini, R. De Santis, L. L. Travaini, et al. Intraoperative Avidination for Radionuclide Therapy: A Prospective New Development to Accelerate Radiotherapy in Breast Cancer Clin. Cancer Res., September 15, 2007; 13(18): 5646s - 5651s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Nye, D. M. Schuster, W. Yu, V. M. Camp, M. M. Goodman, and J. R. Votaw Biodistribution and Radiation Dosimetry of the Synthetic Nonmetabolized Amino Acid Analogue Anti-18F-FACBC in Humans J. Nucl. Med., June 1, 2007; 48(6): 1017 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. Kontogeorgakos, P. A. Dimitriou, G. S. Limouris, and L. J. Vlahos Patient-Specific Dosimetry Calculations Using Mathematic Models of Different Anatomic Sizes During Therapy with 111In-DTPA-D-Phe1-Octreotide Infusions After Catheterization of the Hepatic Artery J. Nucl. Med., September 1, 2006; 47(9): 1476 - 1482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ferrari, M. Cremonesi, M. Bartolomei, L. Bodei, M. Chinol, M. Fiorenza, G. Tosi, and G. Paganelli Dosimetric Model for Locoregional Treatments of Brain Tumors with 90Y-Conjugates: Clinical Application with 90Y-DOTATOC J. Nucl. Med., January 1, 2006; 47(1): 105 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Rutar, S. C. Augustine, D. Colcher, J. A. Siegel, D. A. Jacobson, M. A. Tempero, V. J. Dukat, M. A. Hohenstein, L. S. Gobar, and J. M. Vose Outpatient Treatment with 131I-Anti-B1 Antibody: Radiation Exposure to Family Members J. Nucl. Med., June 1, 2001; 42(6): 907 - 915. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
